Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
- Xeris Biopharma Holdings stock is taking a hit today. What’s weighing on XERS shares?
Lawsuit Targets Two Pharmaceutical Companies
The lawsuit, filed by Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, targets unauthorized generic versions of Recorlev. The lawsuit names Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC as the two companies that have filed new drug applications with the FDA to produce generic versions of Recorlev.
“We are confident in the quality and strength of the intellectual property we have developed for Recorlev,” said John P. Shannon, CEO of Xeris Biopharma. “We have filed this patent infringement lawsuit to vigorously defend our position.”
The lawsuit action underscores its commitment to safeguard its intellectual property through March 2040, backed by Orphan Drug Exclusivity until December 2028. In response to potential threats, Xeris anticipates further challenges from ANDA filers, indicating a readiness to vigorously defend its market position.
Shares Trade Below Key Averages
Over the past year, Xeris Biopharma Holdings, Inc. has seen a notable increase of 61.30% in its stock price, despite current challenges. However, the stock is currently trading below all key moving averages, which signals caution. It is 12.6% below the 20-day SMA, 15.9% below the 50-day SMA, and significantly, 20.2% below the 100-day SMA. This positioning suggests a bearish outlook in the short to medium term.
The technical indicators reinforce this perspective. The RSI stands at 42.31, indicating a lack of strong momentum, while the MACD’s position below the signal line further confirms bearish trends. These indicators suggest that investors might be cautious, watching for potential shifts in the stock’s trajectory.
Earnings & Analyst Outlook
The countdown is on: Xeris Biopharma Holdings, Inc. is set to report earnings on March 2, 2026. With this date rapidly approaching, here’s what analysts and investors are watching:
- EPS Estimate: 4 cents (Up from a loss of 3 cents YoY)
- Revenue Estimate: $84.17 million (Up from $60.10 million YoY)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $11.03. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Maintains Target to $10.00) (Jan. 9)
- Barclays: Initiated with Overweight (Target $9.00) (Dec. 9, 2025)
- Oppenheimer: Outperform (Maintains Target to $18.00) (Nov. 7, 2025)
Shares Trade Lower In Regular Hours
XERS Price Action: Xeris Biopharma Holdings shares were down 10.83% at $6.01 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
Recent Comments